Outcomes of patients treated with SVILE <i>vs</i>. P-GemOx for extranodal natural killer/T-cell lymphoma, nasal type: a prospective, randomized controlled study

Liqiang Wei, Lei Yang, Ye Jin, Jia Cong, Xin Li, Na Yao, H. J. Yang, Xueying Cui, Jing Ding, Yiping Wu, Jingwen WangCancer 2020 · DOI

TL;DR

This study introduces and evaluates SVILE, a novel chemotherapy regimen for extranodal natural killer/T-cell lymphoma, nasal type (ENKTL). The research demonstrates that SVILE is as effective and well-tolerated as the established P-GemOx regimen, offering a comparable therapeutic option for patients with this aggressive cancer.

What Problem Does This Paper Address?

Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is a rare but aggressive cancer, particularly prevalent in East Asia. While treatment options have improved, existing regimens like CHOP are no longer considered ideal due to resistance issues. Newer regimens, often incorporating L-asparaginase, have shown promise, but some, like SMILE, can be associated with significant toxicity, especially in early-stage disease. The authors sought to develop and test a novel regimen, SVILE, that aims to provide comparable efficacy to established treatments like P-GemOx while potentially mitigating some of the toxicity concerns, thus addressing the need for effective and tolerable treatment options for newly diagnosed ENKTL.

Methods

This was a prospective, stratified randomized controlled study involving 103 patients diagnosed with newly diagnosed ENKTL (ND-ENKTL). Patients were stratified by disease stage (I/II vs. III/IV) and then randomly assigned to receive either the novel SVILE regimen (experimental group) or the P-GemOx regimen (control group). Both regimens were followed by radiotherapy and consolidation chemotherapy for patients who responded well. The primary endpoint was the overall response rate (ORR) after three cycles of induction chemotherapy. Secondary endpoints included complete response (CR) rate, progression-free survival (PFS), and overall survival (OS), along with safety evaluations.

The SVILE regimen consisted of ifosfamide, pegaspargase, vindesine, etoposide, and dexamethasone. The P-GemOx regimen comprised gemcitabine, oxaliplatin, and pegaspargase. Both regimens were administered every three weeks. Adverse events were graded using the Common Terminology Criteria for Adverse Events version 3.0.

Datasets

Not discussed in the paper. The study involved direct patient recruitment and treatment.

Key Insights and Ideas

  • Novel Regimen Development: The creation of SVILE represents an effort to refine existing chemotherapy approaches for ENKTL, specifically by replacing methotrexate in the mSMILE regimen with vindesine to potentially reduce toxicity while maintaining efficacy.
  • Direct Comparison: The study's strength lies in its direct, prospective, randomized comparison of a novel regimen (SVILE) against a well-established and effective regimen (P-GemOx) for newly diagnosed ENKTL.
  • Comparable Efficacy: Despite being a novel regimen, SVILE demonstrated comparable short-term and long-term efficacy to P-GemOx across various response metrics (ORR, CR) and survival outcomes (PFS, OS).
  • Favorable Safety Profile: The study suggests that SVILE is well-tolerated, with common adverse events being manageable and reversible, and importantly, no treatment-related deaths were reported. This is a crucial finding, especially considering the toxicity concerns with some other advanced regimens.
  • Stage-Specific Efficacy: While not statistically significant, the observed response rates and survival data showed consistency between the two regimens across different disease stages (I/II and III/IV), indicating broad applicability.

Key Results

  • Overall Response Rate (ORR): After 3 cycles of induction chemotherapy, the ORR was 86.5% for the SVILE group and 88.2% for the P-GemOx group, with no significant difference.
  • Complete Response (CR) Rate: By the end of treatment, the CR rate was 78.8% for SVILE and 84.3% for P-GemOx, again, not statistically different.
  • Stage I/II Patients: For patients with stage I/II disease, the CR rate after treatment was 83.4% for SVILE vs. 97.0% for P-GemOx. The 3-year PFS and OS were 88.3% vs. 93.3% and 88.8% vs. 97.0%, respectively.
  • Stage III/IV Patients: For patients with stage III/IV disease, the CR rate after treatment was 68.8% for SVILE vs. 61.1% for P-GemOx. The 3-year PFS and OS were 46.2% vs. 65.7% and 68.8% vs. 72.2%, respectively.
  • Survival: No significant differences were observed in progression-free survival (PFS) or overall survival (OS) between the SVILE and P-GemOx groups, either overall or when stratified by stage.
  • Adverse Events: The most common adverse events were hematological toxicity, hepatotoxicity, and coagulation abnormalities, which were reversible. No grade 5 adverse events (treatment-related deaths) occurred.

Limitations and Future Work

The authors acknowledge that the number of patients in each group was relatively small. They suggest that larger, multi-center studies are needed to further confirm the efficacy and safety of the SVILE regimen. Future work could also involve exploring the molecular mechanisms behind ENKTL and investigating the potential of SVILE in combination with newer therapies like monoclonal antibodies or immunomodulators for relapsed or refractory cases. The study also mentions ongoing clinical trials for relapsed/refractory ENKTL, indicating continued research in this area.

Summary updated

Abstract

<b>Objective:</b> To compare the efficacy and safety of the novel SVILE regimen with the P-GemOx regimen in patients with newly diagnosed extranodal natural killer/T-cell lymphoma, nasal type (ND-ENKTL). <b>Methods</b>: From April 2015 to July 2018, 103 patients with ND-ENKTL were randomly assigned to SVILE (experimental group) or P-GemOx (control group) chemotherapy followed by radiotherapy and consolidation chemotherapy. The primary endpoint was the overall response rate after 3 cycles of chemotherapy, and secondary study endpoints were complete response (CR), progression-free survival (PFS), and overall survival (OS). Safety was also evaluated. <b>Results:</b> There were no significant differences in baseline characteristics in the experimental <i>vs.</i> control groups. In experimental and control groups, respectively, the overall response rates were 91.7% <i>vs.</i> 97.0% for stage I/II and 75.0% <i>vs.</i> 72.2% for stage III/IV. The CR rates were 83.4% <i>vs.</i> 97.0% for stage I/II and 68.8% <i>vs.</i> 61.1% for stage III/IV. None of those differences were significant. There was no significant difference in PFS and OS between groups and between patients in stage I/II and stage III/IV. The 3-year PFS and OS in stage I/II were 88.3% <i>vs.</i> 93.3% and 88.8% <i>vs.</i> 97.0%, respectively. The 3-year PFS and OS in stage III/IV were 46.2% <i>vs.</i> 65.7% and 68.8% <i>vs.</i> 72.2%, respectively. The common adverse events were hematological toxicity, hepatotoxicity, and coagulation abnormalities, which were found to be reversible with supportive therapy. <b>Conclusions:</b> The novel SVILE regimen has comparable effects to those of P-GemOx in patients with ND-ENKTL and is well tolerated. SVILE is a therapeutic option for ND-ENKTL.
BibTeX
@inproceedings{wei2020outcomes,
  author = {Liqiang Wei and Lei Yang and Ye Jin and Jia Cong and Xin Li and Na Yao and H. J. Yang and Xueying Cui and Jing Ding and Yiping Wu and Jingwen Wang},
  title = {{Outcomes of patients treated with SVILE \&lt;i\&gt;vs\&lt;/i\&gt;. P-GemOx for extranodal natural killer/T-cell lymphoma, nasal type: a prospective, randomized controlled study}},
  booktitle = {Cancer},
  year = {2020},
  doi = {10.20892/j.issn.2095-3941.2020.0160},
}
Figure